Perioperative Dexmedetomidine Improves Outcomes of Cardiac Surgery

• DOI: 10.1161/circulationaha.112.000936
• Publication Date: 2013-03-20T03:38:55Z
• Authors: Fuhai Ji; Zhongmin Li; Hung Nguyen; Nilas Young; Pengcai Shi; Neal Fleming; Hong Liu
• Keywords: Dexmedetomidine

Cardiac surgery is associated with a high risk of cardiovascular and other complications that translate into increased mortality healthcare costs. This retrospective study was designed to determine whether the perioperative use dexmedetomidine could reduce incidence after cardiac surgery. A total 1134 patients who underwent coronary artery bypass plus valvular or procedures were included. Of them, 568 received intravenous infusion 566 did not. Data adjusted propensity scores, multivariate logistic regression used. The primary outcomes measured included postoperative major adverse cardiocerebral events (stroke, coma, myocardial infarction, heart block, arrest). Secondary renal failure, sepsis, delirium, ventilation hours, length hospital stay, 30-day readmission. Dexmedetomidine significantly reduced in-hospital (1.23% versus 4.59%; odds ratio, 0.34; 95% confidence interval, 0.192-0.614; P<0.0001), (1.76% 5.12%; 0.39; 0.226-0.655; 1-year (3.17% 7.95%; 0.47; 0.312-0.701; P=0.0002) mortality. Perioperative therapy also overall (47.18% 54.06%; 0.80; 0.68-0.96; P=0.0136) delirium (5.46% 7.42%; 0.53; 0.37-0.75; P=0.0030). decrease in up 1 year decreased undergoing URL: www.clinicaltrials.gov. Unique identifier: NCT01683448.